Aragen Bioscience expands labs to support rapid growth

02-Oct-2007

For Immediate Release:                                                                 October 2, 2007

Aragen Bioscience, Inc. Expands Labs to Support Rapid Growth

Aragen Bioscience, Inc. (Morgan Hill, CA), a provider of early stage research and development services to the pharmaceutical and biotechnology industry, has moved into a new 17,000 sq. ft. facility to support its aggressive growth.  “The demand for our services and the rate of growth we are experiencing is extremely gratifying“ commented Rick Srigley, Aragen’s President and CEO.  “Our blend of scientific services, encompassing molecular biology, cell biology, immunology, disease modeling, cell line development and protein production, within a single company has proven to be a unique and attractive part of our business model”, Srigley added.

The new labs and offices will be used in support of Aragen’s in vitro services, which include: immunological and cell-based assays for cytokine and other analysis; target screening and mechanism of action studies; cell line development; and protein production and purification.  This new facility is in addition to an existing 8,500 sq. ft. facility dedicated to a diverse range of simple to extremely complex disease modeling studies in rodents.

 “This expansion enables us to confidently plan and implement our business strategy for the next 3-5 years”, Srigley continued. “We are clearly on the cusp of a unique opportunity and are confident that this move will enable us to meet our customers’ expanding needs and continue our rapid growth”.

Aragen Bioscience was formed in January 2006 to acquire the contract services business of Celliance Bioservices (a Serologicals company) previously, Sierra BioSource.  The fourteen year track record of continuous operation from the inception of Sierra BioSource gives Aragen Bioscience a significant experience base and a unique perspective on the bioservices business.

For more information on Aragen Bioscience and the services it offers, please visit http://www.aragenbio.com.

For media relation questions, contact media@aragenbio.com